SOPHiA GENETICS SA

NasdaqGS:SOPH Stock Report

Market Cap: US$248.5m

SOPHiA GENETICS Management

Management criteria checks 3/4

SOPHiA GENETICS' CEO is Jurgi Camblong, appointed in Mar 2011, has a tenure of 13.92 years. directly owns 3.7% of the company’s shares, worth $9.20M. The average tenure of the management team and the board of directors is 4.1 years and 4.7 years respectively.

Key information

Jurgi Camblong

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure13.9yrs
CEO ownership3.7%
Management average tenure4.1yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Shareholders Should Be Pleased With SOPHiA GENETICS SA's (NASDAQ:SOPH) Price

Jan 10
Shareholders Should Be Pleased With SOPHiA GENETICS SA's (NASDAQ:SOPH) Price

Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?

Oct 03
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target

Aug 09
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target

Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)

Aug 08
Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)

SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 09
SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector

Feb 12

Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Dec 27
Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge

Nov 09
Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge

Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?

Aug 08
Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?

Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Dec 15
Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies

Sep 21

SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M

Aug 09

We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely

Jul 01
We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 18
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price

We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth

Mar 10
We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Nov 24
Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

CEO Compensation Analysis

How has Jurgi Camblong's remuneration changed compared to SOPHiA GENETICS's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$73m

Dec 31 2023n/an/a

-US$79m

Sep 30 2023n/an/a

-US$69m

Jun 30 2023n/an/a

-US$78m

Mar 31 2023n/an/a

-US$82m

Dec 31 2022US$3mUS$507k

-US$87m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$93m

Mar 31 2022n/an/a

-US$86m

Dec 31 2021US$8mUS$394k

-US$74m

Compensation vs Market: Insufficient data to establish whether Jurgi's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Jurgi's compensation has been consistent with company performance over the past year.


CEO

Jurgi Camblong (46 yo)

13.9yrs

Tenure

US$3,332,361

Compensation

Dr. Jurgi Camblong, Ph D., M.B.A., serves as Chief Executive Officer and Director of SOPHiA GENETICS SA since March 2011. Dr. Camblong Co-founded SOPHiA GENETICS SA since March 2011.In 2010, Dr. Camblong...


Leadership Team

NamePositionTenureCompensationOwnership
Jurgi Camblong
Co-Founder13.9yrsUS$3.33m3.7%
$ 9.2m
Ross Muken
Presidentless than a yearno data0.093%
$ 230.1k
George Cardoza
Executive VP & CFOless than a yearno datano data
Abhimanyu Verma
Senior VP & CTO3.1yrsno datano data
Zhenyu Xu
Executive VP & Chief Scientific Officer4.1yrsno data0.62%
$ 1.5m
Kellen Sanger
Head of Strategy and Investor Relationsno datano datano data
Daan van Well
Executive VP5.7yrsno data0.14%
$ 343.4k
Manuela Da Valente
Executive VP & Chief People Officer6.1yrsno data0.060%
$ 149.2k
Kevin Puylaert
VP & MD of EMEA1.5yrsno datano data
Philippe Menu
Executive VP5yrsno data0.063%
$ 156.1k

4.1yrs

Average Tenure

46yo

Average Age

Experienced Management: SOPH's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jurgi Camblong
Co-Founder13.9yrsUS$3.33m3.7%
$ 9.2m
Kathy Hibbs
Independent Non-Executive Director4.1yrsUS$257.20k0.056%
$ 139.9k
Didier Hirsch
Independent Non-Executive Director4.7yrsUS$265.94k0.11%
$ 278.7k
Jean-Michel Yves Cossery
Independent Director3.1yrsUS$218.17k0.095%
$ 237.1k
Vincent Ossipow
Independent Non-Executive Director10.7yrsUS$233.53k0.60%
$ 1.5m
Tomer Berkovitz
Independent Non-Executive Director3.9yrsno datano data
Troy Cox
Independent Non-Executive Chairman5.7yrsUS$290.93k0.28%
$ 695.4k

4.7yrs

Average Tenure

60yo

Average Age

Experienced Board: SOPH's board of directors are considered experienced (4.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/26 21:15
End of Day Share Price 2025/02/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SOPHiA GENETICS SA is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
William BonelloCraig-Hallum Capital Group LLC
Katie TryhaneCredit Suisse